Abcam, ab259237, Human VAT1 knockout HEK-293T cell lysate

Size: 1Kit
VAT1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Insertion of the selection cassette in exon1.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Insertion of the selection cassette in exon1.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-VAT1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
VAT1 also known as Vesicle Amine Transport Protein 1 homolog is a protein involved mechanically in the transport and storage of amines in synaptic vesicles. It has an approximate mass of 45 kDa. VAT1 is highly expressed in the nervous system particularly in regions with a high density of synaptic vesicles. It localizes to the membrane of synaptic vesicles suggesting its role in vesicular trafficking and neurotransmitter transport processes.
Biological function summary
VAT1 functions in vesicular transport and neurotransmitter storage playing a role in synaptic transmission. This protein does not work alone; it contributes to a larger complex involved in establishing proper neurotransmitter concentrations within synaptic vesicles. VAT1 may also participate in modulating synaptic plasticity which influences learning and memory processes. Its activity ensures proper nerve signal transmission across synapses by maintaining neurotransmitter levels.
Pathways
The VAT1 protein is important in neurotransmitter release and recycling pathways in the nervous system. It associates with proteins like synaptophysin and synapsin I to facilitate vesicle docking and release. VAT1 plays a role in the synaptic vesicle cycle which includes vesicle loading exocytosis and recycling. Its function guarantees that neurotransmitters are quickly replenished promoting efficient synaptic communication.
VAT1 associates with neurological disorders such as Parkinson’s disease and epilepsy where neurotransmitter imbalances are evident. Connections between VAT1 and the protein alpha-synuclein are apparent in the context of Parkinson’s disease as disruptions in vesicular transport can lead to toxic protein aggregation. In epilepsy disturbances in VAT1 function can impact synaptic efficacy and neurotransmitter availability contributing to seizure activity. Understanding VAT1 function can provide insights into these disorders and offer targets for therapeutic intervention.